AAAAAA
Results: 1-25/27
Authors:
Yasojima, K
Schwab, C
McGeer, EG
McGeer, PL
Citation: K. Yasojima et al., Complement components, but not complement inhibitors, are upregulated in atherosclerotic plaques, ART THROM V, 21(7), 2001, pp. 1214-1219
Authors:
Yasojima, K
McGeer, EG
McGeer, PL
Citation: K. Yasojima et al., 3-Hydroxy-3-methylglutaryl-coenzyme A reductase mRNA in Alzheimer and control brain, NEUROREPORT, 12(13), 2001, pp. 2935-2938
Authors:
Yasojima, K
Akiyama, H
McGeer, EG
McGeer, PL
Citation: K. Yasojima et al., Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of beta-amyloid peptide, NEUROSCI L, 297(2), 2001, pp. 97-100
Authors:
McGeer, PL
McGeer, EG
Yasojima, K
Citation: Pl. Mcgeer et al., Cardiovascular events and COX-2 inhibitors, J AM MED A, 286(22), 2001, pp. 2810-2810
Authors:
Yasojima, K
Tourtellotte, WW
McGeer, EG
McGeer, PL
Citation: K. Yasojima et al., Marked increase in cyclooxygenase-2 in ALS spinal cord - Implications for therapy, NEUROLOGY, 57(6), 2001, pp. 952-956
Authors:
Yasojima, K
McGeer, EG
McGeer, PL
Citation: K. Yasojima et al., Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain, BRAIN RES, 919(1), 2001, pp. 115-121
Authors:
McGeer, PL
McGeer, EG
Citation: Pl. Mcgeer et Eg. Mcgeer, Polymorphisms in inflammatory genes and the risk of Alzheimer disease, ARCH NEUROL, 58(11), 2001, pp. 1790-1792
Authors:
Yasojima, K
Schwab, C
McGeer, EG
McGeer, PL
Citation: K. Yasojima et al., Generation of C-reactive protein and complement components in atherosclerotic plaques, AM J PATH, 158(3), 2001, pp. 1039-1051
Authors:
McGeer, PL
Schulzer, M
McGeer, EG
Citation: Pl. Mcgeer et al., Anti-inflammatory agents as possible protective factors for Alzheimer's disease: Analysis of relevant epidemiological studies, PROG INFLAM, 2001, pp. 53-64
Authors:
McGeer, PL
Yasojima, K
McGeer, EG
Citation: Pl. Mcgeer et al., Innate immunity, autotoxicity and degenerative neurologies, ALZHEIMER'S DISEASE, 2001, pp. 331-339
Authors:
Van Kampen, JM
McGeer, EG
Stoessl, AJ
Citation: Jm. Van Kampen et al., Dopamine transporter function assessed by antisense knockdown in the rat: Protection from dopamine neurotoxicity, SYNAPSE, 37(3), 2000, pp. 171-178
Authors:
Tanhehco, EJ
Yasojima, K
McGeer, PL
McGeer, EG
Lucchesi, BR
Citation: Ej. Tanhehco et al., Preconditioning reduces myocardial complement gene expression in vivo, AM J P-HEAR, 279(3), 2000, pp. H1157-H1165
Authors:
McGeer, PL
McGeer, EG
Yasojima, K
Citation: Pl. Mcgeer et al., Alzheimer disease and neuroinflammation, J NEUR TR-S, (59), 2000, pp. 53-57
Authors:
Yasojima, K
Schwab, C
McGeer, EG
McGeer, PL
Citation: K. Yasojima et al., Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease, BRAIN RES, 887(1), 2000, pp. 80-89
Authors:
Klegeris, A
McGeer, EG
McGeer, PL
Citation: A. Klegeris et al., Inhibitory action of 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide (PK 11195) on some mononuclear phagocyte functions, BIOCH PHARM, 59(10), 2000, pp. 1305-1314
Authors:
McGeer, PL
McGeer, EG
Citation: Pl. Mcgeer et Eg. Mcgeer, Autotoxicity and Alzheimer disease, ARCH NEUROL, 57(6), 2000, pp. 789-790
The peripheral benzodiazepine receptor ligand PK 11195 inhibits arthritis in the MRL-lpr mouse model
Authors:
Waterfield, JD
McGeer, EG
McGeer, PL
Citation: Jd. Waterfield et al., The peripheral benzodiazepine receptor ligand PK 11195 inhibits arthritis in the MRL-lpr mouse model, RHEUMATOLOG, 38(11), 1999, pp. 1068-1073
Authors:
McGeer, EG
McGeer, PL
Citation: Eg. Mcgeer et Pl. Mcgeer, Brain inflammation in Alzheimer disease and the therapeutic implications, CUR PHARM D, 5(10), 1999, pp. 821-836
Authors:
McGeer, PL
McGeer, EG
Citation: Pl. Mcgeer et Eg. Mcgeer, Inflammation of the brain in Alzheimer's disease: implications for therapy, J LEUK BIOL, 65(4), 1999, pp. 409-415
Authors:
Doudet, DJ
Chan, GLY
Jivan, S
DeJesus, OT
McGeer, EG
English, C
Ruth, TJ
Holden, JE
Citation: Dj. Doudet et al., Evaluation of dopaminergic presynaptic integrity: 6-[F-18]fluoro-L-dopa versus 6-[F-18]fluoro-L-m-tyrosine, J CEREBR B, 19(3), 1999, pp. 278-287
Authors:
Yasojima, K
McGeer, EG
McGeer, PL
Citation: K. Yasojima et al., Complement regulators Cl inhibitor and CD59 do not significantly inhibit complement activation in Alzheimer disease, BRAIN RES, 833(2), 1999, pp. 297-301
Authors:
Yasojima, K
McGeer, EG
McGeer, PL
Citation: K. Yasojima et al., Tangled areas of Alzheimer brain have upregulated levels of exon 10 containing tau mRNA, BRAIN RES, 831(1-2), 1999, pp. 301-305
Authors:
Yasojima, K
Schwab, C
McGeer, EG
McGeer, PL
Citation: K. Yasojima et al., Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs, BRAIN RES, 830(2), 1999, pp. 226-236
Authors:
Yasojima, K
Schwab, C
McGeer, EG
McGeer, PL
Citation: K. Yasojima et al., Up-regulated production and activation of the complement system in Alzheimer's disease brain, AM J PATH, 154(3), 1999, pp. 927-936
Authors:
McGeer, PL
McGeer, EG
Citation: Pl. Mcgeer et Eg. Mcgeer, Glial cell reactions in neurodegenerative diseases: Pathophysiology and therapeutic interventions, ALZ DIS A D, 12, 1998, pp. S1-S6